GlaxoSmithKline plc (the 'Company')
The following amendment has been made to the Director/PDMR Shareholding announcement released on 28 July 2021 at 17:32 under RNS No 8169G.
Volume of Ordinary shares allocated to Mr Urs Rohner has been amended from "572.183" to "600.534". The change arises due to an administrative error in the calculation of the number of shares allocated.
All other details remain unchanged. The full corrected announcement is set out below.
Transaction notification
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Sir Jonathan Symonds |
|||
|
b) |
Position/status |
Non-Executive Chairman
|
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 April 2021 to 30 June 2021
|
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£14.05 |
3,113.879 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2021-07-28 |
|||
|
f) |
Place of the transaction
|
N/A |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Mr Charles Bancroft |
|||
|
b) |
Position/status |
Independent Non-Executive Director |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W1053
|
|||
|
b) |
Nature of the transaction |
Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 April 2021 to 30 June 2021
|
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
$39.35 |
1,469.711 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2021-07-28 |
|||
|
f) |
Place of the transaction
|
N/A |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Mr Vindi Banga |
|||
|
b) |
Position/status |
Senior Independent Non-Executive Director |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 April 2021 to 30 June 2021
|
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£14.05 |
645.018 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2021-07-28 |
|||
|
f) |
Place of the transaction
|
N/A |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Dr Anne Beal |
|||
|
b) |
Position/status |
Independent Non-Executive Director |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 April 2021 to 30 June 2021
|
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
$39.35 |
122.409 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2021-07-28 |
|||
|
f) |
Place of the transaction
|
N/A |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Dr Vivienne Cox |
|||
|
b) |
Position/status |
Independent Non-Executive Director |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 April 2021 to 30 June 2021
|
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£14.05 |
600.534 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2021-07-28 |
|||
|
f) |
Place of the transaction
|
N/A |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Ms Lynn Elsenhans |
|||
|
b) |
Position/status |
Independent Non-Executive Director |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W1053
|
|||
|
b) |
Nature of the transaction |
Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 April 2021 to 30 June 2021
|
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
$39.35 |
283.444 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2021-07-28 |
|||
|
f) |
Place of the transaction
|
N/A |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Dr Laurie Glimcher |
|||
|
b) |
Position/status |
Independent Non-Executive Director |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W1053
|
|||
|
b) |
Nature of the transaction |
Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 April 2021 to 30 June 2021
|
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
$39.35 |
1,049.794 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2021-07-28 |
|||
|
f) |
Place of the transaction
|
N/A |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Dr Jesse Goodman |
|||
|
b) |
Position/status |
Independent Non-Executive Director |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W1053
|
|||
|
b) |
Nature of the transaction |
Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 April 2021 to 30 June 2021
|
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
$39.35 |
346.432 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2021-07-28 |
|||
|
f) |
Place of the transaction
|
N/A |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Mr Urs Rohner |
|||
|
b) |
Position/status |
Independent Non-Executive Director |
|||
|
c) |
Initial notification/ amendment |
Amendment |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 April 2021 to 30 June 2021
|
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£14.05 |
600.534 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2021-07-28 |
|||
|
f) |
Place of the transaction
|
N/A |
|||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
